RecruitingNCT06565845

Analysis of Various Treatment Methods of Granulomatous Lobular Mastitis

Analysis of the Clinical Characteristics and Three Treatment Methods of Granulomatous Lobular Mastitis

Sponsor

First Affiliated Hospital of Harbin Medical University

Enrollment

350 participants

Start Date

Aug 19, 2024

Study Type

OBSERVATIONAL

Conditions

Granulomatous Mastitis

Summary

Granulomatous lobular mastitis (GLM) is a rare benign breast disease that is difficult to distinguish from breast cancer based on clinical and imaging findings, and there is currently no standard treatment. This study aims to analyze the clinical characteristics and demographic data of GLM patients and to compare the overall effectiveness of three treatment methods: surgery alone, triple anti-tuberculosis drug therapy alone, and combined surgery with triple anti-tuberculosis drug therapy, with the goal of providing new insights for clinical treatment.

Eligibility

Sex: FEMALEMin Age: 15 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Surgery and triple anti-tuberculosis drug for people with granulomatous mastitis. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 15 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURESurgery

patients underwent complete excision of the inflammatory breast tissue and some surrounding normal tissue under combined intravenous with inhalation anesthesia. Damaged skin was also removed.

DRUGtriple anti-tuberculosis drug

Patients took oral rifampin (450 mg/day), isoniazid (300 mg/day), and ethambutol (15 mg/kg/day).